Discovery of the First-in-class G9a/GLP PROTAC Degrader

Overview

Journal bioRxiv

Date 2024 Mar 11

PMID 38464025

Authors

Julia Velez

Yulin Han

Hyerin Yim

Peiyi Yang

Zhijie Deng

Kwang-Su Park

Md Kabir

H Umit Kaniskan

Yan Xiong

Jian Jin

Affiliations

Soon will be listed here.

Abstract

Aberrantly expressed lysine methyltransferases G9a and GLP, which catalyze mono- and di-methylation of histone H3 lysine 9 (H3K9), have been implicated in numerous cancers. Recent studies have uncovered both catalytic and non-catalytic oncogenic functions of G9a/GLP. As such, G9a/GLP catalytic inhibitors have displayed limited anticancer activity. Here, we report the discovery of the first-in-class G9a/GLP proteolysis targeting chimera (PROTAC) degrader, (MS8709), as a potential anticancer therapeutic. induces G9a/GLP degradation in a concentration-, time, and ubiquitin-proteasome system (UPS)-dependent manner, does not alter the mRNA expression of G9a/GLP and is selective for G9a/GLP over other methyltransferases. Moreover, displays superior cell growth inhibition to the parent G9a/GLP inhibitor UNC0642 in prostate, leukemia, and lung cancer cells and has suitable mouse pharmacokinetic properties for efficacy studies. Overall, is a valuable chemical biology tool to further investigate the functions of G9a/GLP and a potential therapeutic for treating G9a/GLP-dependent cancers.

References

Umit Kaniskan H, Martini M, Jin J . Inhibitors of Protein Methyltransferases and Demethylases. Chem Rev. 2017; 118(3):989-1068. PMC: 5610952. DOI: 10.1021/acs.chemrev.6b00801. View

Galdeano C, Gadd M, Soares P, Scaffidi S, Van Molle I, Birced I . Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities. J Med Chem. 2014; 57(20):8657-63. PMC: 4207132. DOI: 10.1021/jm5011258. View

Sweis R, Pliushchev M, Brown P, Guo J, Li F, Maag D . Discovery and development of potent and selective inhibitors of histone methyltransferase g9a. ACS Med Chem Lett. 2014; 5(2):205-9. PMC: 4027767. DOI: 10.1021/ml400496h. View

Vedadi M, Barsyte-Lovejoy D, Liu F, Rival-Gervier S, Allali-Hassani A, Labrie V . A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol. 2011; 7(8):566-74. PMC: 3184254. DOI: 10.1038/nchembio.599. View

Casciello F, Windloch K, Gannon F, Lee J . Functional Role of G9a Histone Methyltransferase in Cancer. Front Immunol. 2015; 6:487. PMC: 4585248. DOI: 10.3389/fimmu.2015.00487. View

Huang J, Dorsey J, Chuikov S, Zhang X, Jenuwein T, Reinberg D . G9a and Glp methylate lysine 373 in the tumor suppressor p53. J Biol Chem. 2010; 285(13):9636-9641. PMC: 2843213. DOI: 10.1074/jbc.M109.062588. View

Wang Y, Zhang J, Su Y, Shen Y, Jiang D, Hou Y . G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin. Nat Commun. 2017; 8(1):274. PMC: 5561105. DOI: 10.1038/s41467-017-00350-9. View

Li K, Hua K, Lin Y, Su C, Ko J, Hsiao M . Inhibition of G9a induces DUSP4-dependent autophagic cell death in head and neck squamous cell carcinoma. Mol Cancer. 2014; 13:172. PMC: 4107555. DOI: 10.1186/1476-4598-13-172. View

Tachibana M, Sugimoto K, Nozaki M, Ueda J, Ohta T, Ohki M . G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev. 2002; 16(14):1779-91. PMC: 186403. DOI: 10.1101/gad.989402. View

10.

Cao Q, Wang X, Zhao M, Yang R, Malik R, Qiao Y . The central role of EED in the orchestration of polycomb group complexes. Nat Commun. 2014; 5:3127. PMC: 4073494. DOI: 10.1038/ncomms4127. View

11.

Zheng Y, Liu A, Wang Z, Cao Q, Wang W, Lin L . Inhibition of EHMT1/2 rescues synaptic and cognitive functions for Alzheimer's disease. Brain. 2019; 142(3):787-807. PMC: 6391616. DOI: 10.1093/brain/awy354. View

12.

Lehnertz B, Pabst C, Su L, Miller M, Liu F, Yi L . The methyltransferase G9a regulates HoxA9-dependent transcription in AML. Genes Dev. 2014; 28(4):317-27. PMC: 3937511. DOI: 10.1101/gad.236794.113. View

13.

Cheng M, Yu X, Lu K, Xie L, Wang L, Meng F . Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders. J Med Chem. 2020; 63(3):1216-1232. PMC: 7318554. DOI: 10.1021/acs.jmedchem.9b01566. View

14.

Shankar S, Bahirvani A, Rao V, Bharathy N, Ow J, Taneja R . G9a, a multipotent regulator of gene expression. Epigenetics. 2012; 8(1):16-22. PMC: 3549875. DOI: 10.4161/epi.23331. View

15.

Oh S, Kim K, Chae Y, Kang J, Hahn Y, Seo S . H3K9 histone methyltransferase G9a-mediated transcriptional activation of p21. FEBS Lett. 2014; 588(5):685-91. DOI: 10.1016/j.febslet.2014.01.039. View

16.

Chen M, Hua K, Kao H, Chi C, Wei L, Johansson G . H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res. 2010; 70(20):7830-40. DOI: 10.1158/0008-5472.CAN-10-0833. View

17.

Bekes M, Langley D, Crews C . PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022; 21(3):181-200. PMC: 8765495. DOI: 10.1038/s41573-021-00371-6. View

18.

Xiong Y, Zhong Y, Yim H, Yang X, Park K, Xie L . Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets. J Am Chem Soc. 2022; 144(49):22622-22632. PMC: 9772293. DOI: 10.1021/jacs.2c09255. View

19.

Rowbotham S, Li F, Dost A, Louie S, Marsh B, Pessina P . H3K9 methyltransferases and demethylases control lung tumor-propagating cells and lung cancer progression. Nat Commun. 2018; 9(1):4559. PMC: 6242814. DOI: 10.1038/s41467-018-07077-1. View

20.

Tachibana M, Sugimoto K, Fukushima T, Shinkai Y . Set domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. J Biol Chem. 2001; 276(27):25309-17. DOI: 10.1074/jbc.M101914200. View